Annexon Inc., trading under the ticker symbol ANXN on the Nasdaq stock exchange, is a clinical-stage biopharmaceutical company known as Annexon Biosciences. Based in South San Francisco, California, the company is dedicated to developing innovative therapies targeting autoimmune and neurodegenerative diseases that affect the body, eyes, and brain. As a provider of healthcare services, Annexon Biosciences primarily serves patients within the state of California.
In a recent development, Annexon Inc. reported the grant of inducement shares to a new employee, in compliance with Nasdaq Listing Rule 5635(c)(4), on December 17, 2025. This move is part of the company’s strategy to attract and retain top talent in the competitive biopharmaceutical industry.
As of January 1, 2026, the company’s stock closed at $4.69. Over the past year, the share price has experienced significant volatility, reaching a 52-week high of $5.48 on December 21, 2025, and a 52-week low of $1.285 on April 9, 2025. This fluctuation reflects the dynamic nature of the biopharmaceutical sector and the market’s response to the company’s developmental milestones and financial performance.
Annexon Inc.’s financial metrics reveal a price-to-earnings (P/E) ratio of -3.38, indicating that the company is currently not generating positive earnings. This is not uncommon for clinical-stage biopharmaceutical companies, which often invest heavily in research and development before achieving profitability. Despite the negative P/E ratio, the company’s price-to-book (P/B) ratio stands at 4.72, suggesting that the market values the company significantly above its book value. This valuation reflects investor confidence in the company’s potential to bring successful therapies to market.
With a market capitalization of approximately $725.62 million, Annexon Inc. continues to focus on advancing its pipeline of novel therapies. The company’s efforts are aimed at addressing unmet medical needs in autoimmune and neurodegenerative diseases, positioning it as a key player in the healthcare sector.
For more detailed information about Annexon Inc. and its ongoing projects, stakeholders and interested parties are encouraged to visit the company’s official website at www.annexonbio.com .
